Surf Therapeutics
Stanford spin-out developing a non-invasive ultrasound neuromodulation platform to treat autoimmune disorders such as rheumatoid arthritis. Its at-home device is designed for short daily use, offering a new approach to managing inflammation without drugs or surgery.
INDUSTRY
Medical Technology, Neuromodulation
SECTOR
MedTech / Neuromodulation / Autoimmune Disease
FOCUS
Autoimmune Disease, Inflammation Modulation
TECHNOLOGY
Ultrasound-Based Neuromodulation
STAGE OF INVESTMENT
Seed
HEADQUARTERS
Austin, TX
WEBSITE
www.surftherapeutics.com
Millions of patients with autoimmune disease still cycle through therapies that do not work well enough for them. Surf is pursuing a fundamentally different approach, using non-invasive ultrasound to activate the body’s own anti-inflammatory pathway without another drug or surgical implant
Chris Yoo, PhD
Fund Manager
What they do.
Surf Therapeutics is developing a non-invasive ultrasound neuromodulation platform designed to treat chronic inflammatory disorders. Its broad-beam ultrasound technology stimulates the body’s cholinergic anti-inflammatory pathway, with the goal of reducing inflammation without drugs or implanted hardware and eventually enabling treatment from home.
Why we invested.
Surf stood out because it is pursuing a fundamentally different approach to autoimmune disease, using non-invasive neuromodulation rather than another pharmaceutical therapy. The technology grew out of Stanford research and has advanced into human clinical development, giving us both a differentiated scientific thesis and early evidence that the platform can move beyond the lab.
Leadership
Nishant Doctor, MS
CEO & Co-Founder
Alex Sackeim, MD
CMO & Co-Founder
